<iframe src="http://www.googletagmanager.com/ns.html?id=GTM-K5Z6KH" height="0" width="0" style="display:none;visibility:hidden">


Thync demonstrated the first effective use of bioelectronics to treat psoriasis in a 2017 pilot study.

Bioelectronic therapies are being developed to effectively treat a number of disorders, that currently can only be addressed using pharmaceutical interventions.

Thync is focused on developing safe, non-invasive, bioelectronic therapies for mental health, inflammatory disorders, and skin conditions.

A growing body of scientific literature demonstrates the important role the nervous system plays in regulating the body’s immune response. These findings support the use of modulating the peripheral nervous system to potentially treat chronic inflammatory conditions such as Psoriasis, Lupus, IBD, and Rheumatoid Arthritis.

Thync's bioelectronic platform targets cervical and thoracic spinal nerves to systemically modulate autonomic nervous system activity. Proprietary electrical neuromodulation programs are used to provide high efficacy without any pain or discomfort. These neural pathways are involved in a number of important disease processes including the immune response.

2017 Psoriasis Pilot Study

In the single-blind study, 28 subjects used either a treatment program or an active placebo program daily for 10 minutes over 4 weeks. After 4 weeks, 15 of the 18 subjects in the treatment group (83%) reported at least a 50% reduction in psoriasis symptoms. Six subjects out of 18 reported more than a 75% reduction of these symptoms. In comparison, only 2 of 10 subjects (20%) within the active placebo control group reported a 50% reduction in symptoms with no one (0/10) reporting a 75% improvement (p = 0.0005).

Thync is currently pursuing clinical trials in partnership with UCSF to further validate noninvasive autonomic modulation as a treatment for plaque psoriasis.

Scientific Publications
Nature Reports